DE69431060D1 - Klonierte glutaminsäure-decarboxylase - Google Patents

Klonierte glutaminsäure-decarboxylase

Info

Publication number
DE69431060D1
DE69431060D1 DE69431060T DE69431060T DE69431060D1 DE 69431060 D1 DE69431060 D1 DE 69431060D1 DE 69431060 T DE69431060 T DE 69431060T DE 69431060 T DE69431060 T DE 69431060T DE 69431060 D1 DE69431060 D1 DE 69431060D1
Authority
DE
Germany
Prior art keywords
glutamic acid
acid decarboxylase
cloned
cloned glutamic
gad
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69431060T
Other languages
English (en)
Other versions
DE69431060T2 (de
Inventor
J Tobin
G Erlander
L Kaufman
J Clare-Salzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of DE69431060D1 publication Critical patent/DE69431060D1/de
Publication of DE69431060T2 publication Critical patent/DE69431060T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
DE69431060T 1993-09-17 1994-08-24 Klonierte glutaminsäure-decarboxylase Expired - Lifetime DE69431060T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/123,859 US5674978A (en) 1990-09-21 1993-09-17 Peptides derived from glutamic acid decarboxylase
PCT/US1994/009478 WO1995007992A2 (en) 1993-09-17 1994-08-24 Cloned glutamic acid decarboxylase

Publications (2)

Publication Number Publication Date
DE69431060D1 true DE69431060D1 (de) 2002-08-29
DE69431060T2 DE69431060T2 (de) 2002-11-14

Family

ID=22411325

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69431060T Expired - Lifetime DE69431060T2 (de) 1993-09-17 1994-08-24 Klonierte glutaminsäure-decarboxylase

Country Status (11)

Country Link
US (5) US5674978A (de)
EP (1) EP0719340B1 (de)
JP (1) JP3133339B2 (de)
KR (1) KR100367943B1 (de)
AT (1) ATE221125T1 (de)
AU (1) AU697058B2 (de)
CA (1) CA2170523C (de)
DE (1) DE69431060T2 (de)
DK (1) DK0719340T3 (de)
ES (1) ES2179077T3 (de)
WO (1) WO1995007992A2 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE268908T1 (de) 1990-09-07 2004-06-15 Univ California Verfahren zur diagnose und behandlung von diabetes
US6682906B1 (en) * 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
IL101872A0 (en) * 1991-05-15 1992-12-30 Univ Washington Cloning and expression of human islet glutamic acid decarboxylase autoantigen
US5691448A (en) * 1992-12-03 1997-11-25 Baekkeskov; Steinunn Reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome
CA2140591A1 (en) * 1994-01-20 1995-07-21 Josef Endl Antigen-specific, activated t lymphocytes, detection and use
WO1996026218A1 (en) * 1995-02-20 1996-08-29 Amrad Operations Pty. Ltd. Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)
US5840307A (en) * 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
US5945401A (en) * 1995-06-23 1999-08-31 Conlon; Paul J. Peptide analogues of the 65KD isoform of human glutamic acid decarboxylase and uses thereof
DE19525784A1 (de) * 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
DE19526561A1 (de) * 1995-07-20 1997-01-23 Boehringer Mannheim Gmbh In-vivo-Diabetes-Test
WO1997036618A1 (fr) * 1996-04-01 1997-10-09 Chugai Seiyaku Kabushiki Kaisha Composition diagnostique pour maladies s'accompagnant de reactions auto-immunes declenchees par la decarboxylase d'acide 65k-glutamique
US7361331B2 (en) 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
US6815174B1 (en) * 1996-11-28 2004-11-09 Edgardo Poskus Thioredoxin-glutamate decarboxylase 65 fusion protein
FR2759701B1 (fr) * 1997-02-19 1999-06-04 Inst Nat Sante Rech Med Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques
AU739373B2 (en) * 1997-10-17 2001-10-11 Trustees Of The University Of Pennsylvania, The Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
SE9704451D0 (sv) * 1997-11-28 1997-11-28 Diamyd Therapeutics Ab New method and compositions for the treatment of autoimmune diseases
AU2566799A (en) * 1998-01-27 1999-08-09 Jane Pei-Fan Bai Chemical derivatives of autoantigens and autoimmune-suppressive peptides and pharmaceutical composition containing the same
US6303325B1 (en) 1998-05-29 2001-10-16 Dade Behring Inc. Method for detecting analytes
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
JP2003513886A (ja) * 1999-08-23 2003-04-15 バージニア メイソン リサーチ センター 糖尿病の治療及び予防のためのペプチド及びペプチド類似体
US6436401B1 (en) 1999-09-14 2002-08-20 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
US6713058B2 (en) 1999-09-14 2004-03-30 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
DE50114032D1 (de) * 2000-04-10 2008-07-31 Merk Und Kollegen Gmbh Lab Dr Fusionsprotein zur gleichzeitigen Erkennung von humanen Autoantikörpern
CA2406496A1 (en) 2000-04-19 2001-11-01 Research Corporation Technologies, Inc. Diagnostic assay for endometriosis
US7178152B2 (en) * 2001-03-01 2007-02-13 Sony Corporation Application programming interface for communication between audio/video file system and audio video controller
AU2002256168B2 (en) * 2001-04-10 2007-09-20 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic uses of antibody specificity profiles
US20050130245A1 (en) * 2001-09-17 2005-06-16 Syn X Pharma, Inc. Diagnosis and treatment of early pre-type-1 diabetes utilizing neuronal proteins
US20050004001A1 (en) * 2002-10-02 2005-01-06 Robert Harris Formulation of antigen
US20050250691A1 (en) * 2004-05-10 2005-11-10 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
EP1755631A2 (de) * 2004-03-03 2007-02-28 Diamyd Medical AB Immunomodulation mittels therapeutischer verabreichung von medikamenten zur behandlung von diabetes und vorbeugung von autoimmuner diabetes
US20050209138A1 (en) * 2004-03-19 2005-09-22 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
US7994279B2 (en) * 2006-04-04 2011-08-09 The University Of Toledo Altered peptide ligands of GAD65
CN100450552C (zh) * 2006-05-26 2009-01-14 中国医学科学院医学生物学研究所 Ⅰ型糖尿病疫苗及其构建方法
US20090098631A1 (en) * 2006-08-01 2009-04-16 Neurologix, Inc. Novel glutamic acid decarboxylase (GAD) proteins and methods of use
US20100279422A1 (en) * 2006-08-21 2010-11-04 Cmed Technologies Ltd. Method of surface plasmon resonance (spr) technology to detect genomic disorders for prenatal diagnosis
US20100086920A1 (en) * 2006-09-18 2010-04-08 Cmed Technologies Ltd. Method to assess cancer susceptibility and differential diagnosis of metastases of unknown primary tumors
GB2454852B (en) * 2006-09-19 2011-06-29 Limited Cmed Technologies A method for screening of infectious agents in blood
US20100047815A1 (en) * 2006-09-21 2010-02-25 Cmed Technologies Ltd. Method to detect tumor markers and diagnosis of undifferentiated tumors
WO2008070223A2 (en) * 2006-09-21 2008-06-12 Cmed Technologies Ltd. A method to remove repetitive sequences from human dna
WO2008082710A2 (en) * 2006-09-25 2008-07-10 Cmed Technologies Ltd. A method of surface plasmon resonance (spr) technology to detect genomic aberrations in patients with multiple myeloma
WO2008094312A2 (en) * 2006-09-25 2008-08-07 Cmed Technologies Ltd. A method of surface plasmon resonance (spr) technology to detect genomic disorders for postnatal diagnosis
US20090311699A1 (en) * 2006-09-25 2009-12-17 Cmed Technologies Ltd. Method of surface plasmon resonance (spr) to detect genomic aberrations in patients with chronic lymphocytic leukemia
WO2008085554A2 (en) * 2006-09-25 2008-07-17 Cmed Technologies Ltd. A method to detect virus related immunologigal markers for the diagnosis of hepatitis b virus infection
WO2008057652A2 (en) * 2006-09-25 2008-05-15 Cmed Technologies Ltd. A method to detect virus related immunological markers for the diagnosis of hepatitis c virus infection
US8158342B2 (en) * 2006-09-25 2012-04-17 Cmed Technologies Ltd. Method for the identification of human immunodeficiency virus related antibodies in blood
US8110409B2 (en) * 2006-09-27 2012-02-07 Cmed Technologies Ltd. Method to measure serum biomarkers for the diagnosis of liver fibrosis
WO2008067003A2 (en) * 2006-09-27 2008-06-05 Cmed Technologies Ltd. A method to detect virus related immunological markers for the diagnosis of respiratory tract infections
WO2008067008A2 (en) * 2006-09-27 2008-06-05 Cmed Technologies Ltd. A method for the quantitative evaluation of sex hormones in a serum sample
US20100086937A1 (en) * 2006-09-27 2010-04-08 Cmed Technologies Ltd. method to detect treponema pallidum immunological markers for the diagnosis of syphilis
WO2008066997A2 (en) * 2006-09-27 2008-06-05 Cmed Technologies Ltd. A method for quantitative measurement of cardiac biochemical markers
WO2008066994A2 (en) * 2006-09-27 2008-06-05 Cmed Technologies Ltd. Application of surface plasmon resonance technology to maternal serum screening for congenital birth defects
US8110408B2 (en) * 2006-09-28 2012-02-07 Cmed Technologies Ltd. Method for quantitative detection of diabetes related immunological markers
WO2008067007A2 (en) * 2006-09-28 2008-06-05 Cmed Technologies Ltd. A method for quantitative measurement of thyroid homrones and related antibodies in a serum sample
WO2008111634A1 (ja) * 2007-03-15 2008-09-18 Reverse Proteomics Research Institute Co., Ltd. 脳・神経に特異的あるいは神経分化に特異的なバイオマーカー
EP3214179B1 (de) 2007-03-16 2021-03-03 Genomatica, Inc. Zusammensetzungen und verfahren für die biosynthese von 1,4-butandiol und dessen vorläufern
CA2684453A1 (en) * 2007-04-24 2008-10-30 Diamyd Therapeutics Ab Medicaments and methods to treat autoimmune disease and cancer
US7947483B2 (en) 2007-08-10 2011-05-24 Genomatica, Inc. Methods and organisms for the growth-coupled production of 1,4-butanediol
US8168379B2 (en) 2007-10-04 2012-05-01 Cmed Technologies Ltd. Application of surface plasmon resonance technology for detecting and genotyping HPV
JP5912529B2 (ja) 2008-09-10 2016-04-27 ゲノマチカ， インク． １，４−ブタンジオールの生成のための微生物体
BRPI0922122A2 (pt) 2008-11-30 2017-08-01 Immusant Inc composições e métodos para tratamento de doença celíaca.
EP2438036B1 (de) 2009-06-04 2017-03-08 Genomatica, Inc. Verfahren zur trennung von komponenten einer fermentierungsbrühe
MY187676A (en) 2009-06-04 2021-10-08 Genomatica Inc Microorganisms for the production of 1,4-butanediol and related methods
JP2013507145A (ja) 2009-10-13 2013-03-04 ゲノマチカ， インク． １，４−ブタンジオール、４−ヒドロキシブタナール、４−ヒドロキシブチリル−ＣｏＡ、プトレシン及び関連化合物の生成のための微生物体並びに関連する方法
WO2011066076A1 (en) 2009-11-25 2011-06-03 Genomatica, Inc. Microorganisms and methods for the coproduction of 1,4-butanediol and gamma-butyrolactone
US8445244B2 (en) 2010-02-23 2013-05-21 Genomatica, Inc. Methods for increasing product yields
US8048661B2 (en) 2010-02-23 2011-11-01 Genomatica, Inc. Microbial organisms comprising exogenous nucleic acids encoding reductive TCA pathway enzymes
EP2836845B1 (de) 2012-04-13 2018-05-09 DiabetOmics, Inc. Biomarker für schwangerschaftsdiabetes
WO2013184602A2 (en) 2012-06-04 2013-12-12 Genomatica, Inc. Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds
WO2015038624A1 (en) 2013-09-10 2015-03-19 Immusant, Inc. Dosage of a gluten peptide composition
EP3760224A3 (de) * 2014-06-04 2021-03-31 Diamyd Medical AB Neuartige kombinationen für antigenbasierte therapie
CA2962933A1 (en) 2014-09-29 2016-04-07 Immusant, Inc. Use of hla genetic status to assess or select treatment of celiac disease
AU2015349728A1 (en) 2014-11-21 2017-07-13 Immusant, Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
TWI655812B (zh) 2016-07-20 2019-04-01 松下知識產權經營股份有限公司 懸吊型插座
GB202210967D0 (en) * 2022-07-27 2022-09-07 Univ Birmingham Tolerogenic peptides i

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624926A (en) * 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
US4487830A (en) * 1982-05-14 1984-12-11 American Hoechst Corporation Enzyme/immunofluorescent assay for autoantibodies
EP0138854B1 (de) * 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigen aktive aminosäuresequenzen
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
KR910700459A (ko) * 1988-12-13 1991-03-15 수잔 우레이 인슐린 의존성 진성당뇨병의 조기검진 및 치료를 위한 방법 및 조성물
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) * 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
NO306996B1 (no) * 1989-02-17 2000-01-24 Bayer Ag Isolert bukspyttkjerteloey-celle-(ICA)-antigen for in vitro- bruk
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
JP2649103B2 (ja) * 1990-08-17 1997-09-03 ユニバーシティー オブ フロリダ インシュリン依存性真性糖尿病の早期検出及び処置のための方法及び組成物
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US5475086A (en) * 1990-09-21 1995-12-12 The Regents Of The University Of California Cloned glutamic acid decarboxylase peptides
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
AU8864791A (en) * 1990-10-02 1992-04-28 Trigen Incorporated Antibodies and methods for diagnosis and treatment of diabetes
JP3027190B2 (ja) * 1991-02-22 2000-03-27 アムラド・コーポレイション・リミテッド グルタミン酸デカルボキシラーゼ自己抗原関連疾患の診断及び処置方法
IL101872A0 (en) * 1991-05-15 1992-12-30 Univ Washington Cloning and expression of human islet glutamic acid decarboxylase autoantigen
AU661684B2 (en) * 1991-06-18 1995-08-03 Regents Of The University Of California, The Cloned glutamic acid decarboxylase
US5200318A (en) * 1992-05-13 1993-04-06 Miles Inc. Diagnosis of IDDM with a panel of immunoreagents
US5837477A (en) * 1993-01-15 1998-11-17 The United States Of America As Represented By The Department Of Health And Human Services T cell receptor ligands and methods of using same
KR960700739A (ko) * 1993-03-05 1996-02-24 카린 이스텀 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)
US5547847A (en) * 1993-09-07 1996-08-20 University Of Washington Diagnosis of insulin-dependent diabetes

Also Published As

Publication number Publication date
US6455267B1 (en) 2002-09-24
CA2170523A1 (en) 1995-03-23
KR100367943B1 (ko) 2003-06-18
WO1995007992A3 (en) 1995-06-22
EP0719340A1 (de) 1996-07-03
DE69431060T2 (de) 2002-11-14
EP0719340B1 (de) 2002-07-24
US8926966B1 (en) 2015-01-06
WO1995007992A2 (en) 1995-03-23
JP3133339B2 (ja) 2001-02-05
US5674978A (en) 1997-10-07
AU697058B2 (en) 1998-09-24
US5846740A (en) 1998-12-08
AU7920194A (en) 1995-04-03
DK0719340T3 (da) 2002-11-18
ES2179077T3 (es) 2003-01-16
ATE221125T1 (de) 2002-08-15
CA2170523C (en) 2010-03-30
US6011139A (en) 2000-01-04
JPH09503387A (ja) 1997-04-08
KR960705051A (ko) 1996-10-09

Similar Documents

Publication Publication Date Title
DE69431060T2 (de) Klonierte glutaminsäure-decarboxylase
CA2259163A1 (en) Nt-3 and bdnf analogs having improved circulating life and/or absorption
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
EA199800946A1 (ru) Концентрированный препарат антител
WO1996019580A3 (en) Telomerase protein component
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
GB2367061A (en) Peptides
RU94041224A (ru) Пептиды с органозащитной активностью, фармацевтическая композиция на их основе и их применение в терапии
HUT66309A (en) Bpc peptides, their preparation and therapeutic use
ES2177625T3 (es) Citoquina cc-1 humana circulante.
ES2058479T3 (es) Compuestos peptidicos.
AU1086888A (en) Primary biliary cirrhosis autoantigen
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
CA2070004A1 (en) Cloned glutamic acid decarboxylase
DE3650035T2 (de) THF-Zusammensetzungen.
FI960839A0 (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
EP0317279A3 (de) Peptide für die Verwendung zur Reinigung von Faktor-VIII
DE68914397D1 (de) Menschliches Lymphotoxin.
MX9800239A (es) Metodos para el tratamiento y prevencion de diabetes.
ES2114170T3 (es) Peptidos con actividad organo-protectora, su procedimiento de preparacion y su utilizacion en la terapia.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition